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Abstract
Introduction: Papillary Glioneuronal Tumor (PGNT) is a grade I tumor which was classified as a separate entity in the
World Health Organization Classification of the Central Nervous System 2007 in the group of mixed glioneuronal tumors.
This tumor is rare and subclassifying PGNT represents a challenge. Recently, a fusion between SLC44A1 and PRKCA
which encodes a protein kinase C involved in MAPK signaling pathway has been described in two studies (five cases).
The current study aimed at raising the cytogenetic, histological and molecular profiles of PGNT and to determine if
SLC44A1-PRKCA fusion represented a specific diagnostic marker to distinguish it from other glioneuronal tumors.
Results: We report on four pediatric cases of PGNT, along with clinico-radiologic and immunohistological features
for which SLC44A1-PRKCA fusion assessment by fluorescence in situ hybridization, BRAF V600E and FGFR1 mutation
by immunohistochemistry and direct DNA sequencing and KIAA1549-BRAF fusion by RT-PCR were performed. MAPK
signaling pathway activation was investigated using phospho-ERK immunohistochemistry and western blot. We analyzed
fifteen cases of tumors with challenging histological or clinical differential diagnoses showing respectively a papillary
architecture or periventricular location (PGNT mimics). fluorescence in situ hybridization analysis revealed a constant
SLC44A1-PRKCA fusion signal in all PGNTs. None of PGNT mimics showed the SLC44A1-PRKCA fusion signal pattern.
All PGNTs were negative for BRAF V600E and FGFR1 mutation, and KIAA1549-BRAF fusion. Phospho-ERK analysis provides
arguments for the activation of the MAPK signaling pathway in these tumors.
Conclusions: Here we confirmed and extended the molecular data on PGNT. These results suggest that PGNT belong to
low grade glioma with MAPK signaling pathway deregulation. SLC44A1-PRKCA fusion seems to be a specific characteristic
of PGNT with a high diagnostic value and detectable by FISH.
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Introduction
Mixed neuronal-glial tumors, a category in the World
Health Organization (WHO) Classification of the Central
Nervous System, are heterogeneous and composed of
variably differentiated neuronal and glial cells.
Papillary Glioneuronal Tumor (PGNT) is a grade I glio-
neuronal tumor which was first described by Komori and
colleagues in 1998 [1]. Recognized in WHO 2000 classifi-
cation as a variant of ganglioglioma, PGNT was classified
as a separate entity in WHO 2007 classification [2].
This tumor is rare, with approximately 70 cases reported in
the last decade [3, 4]. Classifying PGNT is a challenge with a
diagnosis generally based on neuroimaging and histology.
However, the magnetic resonance imaging (MRI) characteris-
tics are not specific, highlighting well-demarcated lesions
usually near the ventricles, and are rather used to search for
arguments against the PGNT-mimics tumors as IV ventricle,
pineal or intracortical locations. Histologically, PGNT presents
a biphasic and biphenotypic differentiation and is character-
ized by a glial component arranged in papillary architecture
overlaying hyalinized vessels, associated with interpapillary
regions containing homogeneous oligodendrocyte-like,
neurocyte-like cells, ganglioid-cells and ganglion cells [2].
Studies examining genetic alterations in PGNT are few.
Their molecular characteristics are not yet completely clear.
Gain and structural abnormalities of chromosome 7, isolated
or among other abnormalities have been described. However,
no EGFR gene amplification has been observed [5, 6]. Fusion
genes or mutations involving BRAF, FGFR1 and the MAPK
pathway have been described in other glioneuronal or
glial tumors such as ganglioglioma or pilocytic astrocytoma
[7–10]. BRAF mutation has been analyzed in only two cases,
which were negative [6]. A single case report described a
FGFR1 mutation by pyrosequencing (FGFR1 N546K) but no
large pediatric low grade gliomas (pLGG) cohort studying
FGFR1 mutational status have included some PGNT investi-
gating FGFR1 mutation in PGNT [11]. Yet, to our knowledge,
KIAA-BRAF fusion has not been studied in PGNT. Bridge and
colleagues identified a recurrent chromosomal translocation
t(9;17)(q31;q24), with a resultant oncogenic fusion protein
SLC44A1-PRKCA, in three PGNTs. This fusion is detectable
by conventional cytogenetic analysis and fluorescence in situ
hybridization (FISH) [12]. A recent study has confirmed the
presence of the fusion in two additional PGNTs [13].
In the current study, we investigated four pediatric cases of
PGNT, along with clinico-radiologic, follow-up and immu-
nohistological features, including BRAF (mutation and fu-
sion) and FGFR1 status, for the SLC44A1-PRKCA fusion by
FISH analysis. In addition, in order to demonstrate MAPK
pathway activation, we analyzed phospho-ERK expression by
IHC and western blot. Moreover, we analyzed fifteen cases
of rare tumors either showing a papillary architecture or
presenting within the clinico-radiological differential diagno-
sis of pediatric neuro-oncology (PGNT mimics).
Materials and methods
Tumor samples
The study was carried out on four cases classified as PGNTat
the time of initial diagnosis. Likewise, two gangliogliomas with
papillary architecture, two ANETs, five RGNTs, two PRPs,
one PE, two neurocytomas and one astroblastoma were col-
lected for this study (PGNT mimics). With the exception of
one case from Lariboisière Hospital, all cases were retrieved
from the pathology archives of Sainte-Anne-Necker Hospital
and were subject to a local histopathological review (PV).
Sections for genetic analyses and immunohistochemistry were
prepared from zinc formalin-fixed paraffin-embedded tissue
specimens (formalin 5 %, zinc 3 g/L, sodium chloride 8 g/L).
Immunohistochemistry
Immunostaining was performed at the time of initial diag-
nosis. Representative zinc formalin-fixed sections were
deparaffinized and were subject to a Ventana autostainer
(BenchMark XT, Ventana Medical Systems or Discovery
XT, Ventana Medical Systems) according to standard proto-
col. The following primary antibodies were used: Glial Fibril-
lary Acidic Protein (GFAP) (1:200, 6 F2, Dako Denmark
A/S, Glostrup, Denmark), synaptophysin (1:20, SY38, Pro-
gen Biotechnik GmbH, Heidelberg, Germany), CD34 (1:40,
QBEnd-10, Dako, Denmark A/S, Glostrup, Denmark),
chromogranin A (1:200, LK2H10, Diagnostic BioSystems,
Pleasanton, USA), phospho-FGFR1 (Y653/654) (1:75,
PA5-12594, Thermoscientific, Waltham, USA), p53 (1:5000,
DO-1, Santa Cruz Biotechnology, Dallas, USA), BRAF
V600E (1:100, VE1, Spring Bioscience, Pleasanton, USA),
histone H3.3 K27M mutation (1:1000, ABE419, EMD
Millipore, Billercia, USA). The chromogen diaminobenzidine
was employed. Slide scanning was performed using Nano-
Zoomer 2.ORS (Hamamatsu photonics, Hamamatsu, Japan).
SLC44A1-PRKCA FISH analysis
Molecular cytogenetic (FISH) analysis was performed on
representative tumor sections (4 μm) part as described by
Bridge and colleagues [12] using prelabeled (5-TAMRA or
5-fluorescein-deoxyuridine triphosphate) bacterial artificial
chromosome (BAC) probes (Empire Genomics, Buffalo,
NY), covering SLC44A1 on 9q31 region (RP11-24 J9, RP11-
1097P14, RP11-95O7, RP11-235C23) and PRKCA on 17q24
region (RP11-98C3, RP11-188A11, RP11-1036I14, RP11-
51D14, RP11-52B5). The genomic location of each BAC set
was verified by hybridization to metaphase chromosomes of
normal peripheral blood lymphocytes.
FISH study was performed on interphase nuclei following
standard procedures. Briefly, four-micron sections of tumor
were mounted on SuperFrost Plus slides (Erie Scientific CA.,
Portsmouth, NH) and the area to be probed was determined
in accordance with hematoxylin and eosin stained section.
The sections were deparaffinised in xylene, rehydrated
through an ethanol series air-dried and incubated in pre-
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treatment solution (1 M NaSCN-tris) at 80 °C for 25 min.
Slides were then treated with a 0.01 % pepsin solution
(Sigma-Aldrich, Saint Louis, USA) at 37 °C for 10 min. After
dehydration, 10 μl of probe mixture was applied to each
sample, slides were coverslipped and codenatured at 73 °C
for 2 min and hybridized at 37 °C for 24 h using thermobrite
system (Leica Biosystems, Richmond, IL). A post-
hybridization wash was performed in 2xSSC at 73 °C for
2 min. Preparations were dehydrated and counterstained with
4,6-diamidino-phenyl-indole (DAPI). Signals were scored in
at least 100 non-overlapping interphase nuclei. A negative
control was included (brain parenchyma in tumor periphery).
Positive control consisted of three cases of PGNT confirmed
by Bridge and colleagues as described in the original article
[12]. Specimens were considered SLC44A1-PRKCA positive if
signal fusion(s) were detected in more than 20 % of nuclei
analyzed. Results were recorded using a DM600 imaging
fluorescence microscope (Leica Biosystems, Richmond, IL)
fitted with appropriate filters, a CCD camera, and digital
imaging software from Leica (Cytovision, v7.4).
BRAF molecular analysis
DNA was extracted from 20-μm-section paraffin embedded
tumor samples after a 24 h digestion by proteinase K, using
the DNeasy Tissue Kit and the QIAcube automated
extractor (Qiagen, Hilden, Germany). Yield and quality of
DNA were evaluated by Qubit fluorometer (Invitrogen,
Carlsbad, CA). Direct Sanger sequencing for mutational
assessment of exon 15 of BRAF was performed following
PCR amplification as previously described [14]. PCR was
carried out on 20 ng of DNA in 10 μl final volume and 1 U
of Hot Start Taq polymerase (Qiagen). The amplified
products were studied by direct sequencing after clean-up
exonuclease ExoSAP-IT (Affymetrix, Santa Clara, CA) using
the Big Dye Terminator Cycle Sequencing Kit and capillary
electrophoresis on the automated sequencer ABI3730
(Applied Biosystems, Carlsbad, CA). Sense and antisense se-
quences were screened for exonic alterations using SeqScape
v2.5 software (Applied Biosystems) and compared with the
NCBI reference sequences: BRAF (NM_004333.4).
KIAA1549-BRAF qRT-PCR analysis
RNA was purified from tissue section with RNeasy Micro Kit
(Qiagen) according to the manufacturer’s recommendations.
Hydrolysis probe assays to detect K-B exon junctions
were designed according to Tian and colleagues and pur-
chased from Life Technologies (Darmstradt, Germany) [15].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was used as internal control. PCR amplification was
carried out on cDNA from 10 ng of RNA using AmpliTaq
Gold DNA polymerase (Life Technologies). Reactions were in
duplicate with incubation at 50 °C for 2 min, then 95 °C for
10 min, and then for 50 cycles of 95 °C for 15 s and 60 °C for
1 min. Fluorescence was recorded and cycles to threshold
(CT) are calculated using ViiA7 RUO Software (Life Tech-
nologies). A reference of total RNA obtained from non-
neoplastic cerebellum tissue sample (Stratagene, LA Jolla,
CA) was used as negative control. The positive control for
KIAA1549-BRAF was RNA with known breakdown junction,
which was provided by Dr Jones in Heidelberg.
FGFR1 molecular analysis
We extracted DNA from 4 μm formalin fixed paraffin em-
bedded tumor sections blades. Each blade was accompanied
by a blade coloured with Hématoxyline-Eosine-Safran (HES)
on which the zone containing the tumorous cells was em-
phasized by strapping and the proportion of tumorous cells
indicated. The first stage consisted in dewaxing by Micro-
clearing® (DiaPath, Italy) followed by slow tissue rehydration.
DNA were purified by automated extraction on EVO75
(Tecan), according to the Macherey-Nagel protocol; NR
(NucleoSpin® 96 Blood; NucleoSpin® 8 Viruses Binding
Strips; Macherey Nagel). We used qPCR-High Resolution
Melting (qPCR-HRM) for FGFR1 exon 12 and 14 as a
screening technique, allowing avoiding useless sequencing of
not mutated samples [16]. We used touchdown PCR condi-
tions with one step 95 °C 10 min and 45 cycles (95 °C 10 s,
65 °C to 58 °C (0.5 °C); 72 °C 30 s). Classification is deter-
mined by sequencing Sanger [17], (MixBigDye® 5X, Roche)
after DNA purification (ExoSap-IT®), pipeting being
automated on Evo75®, (Tecan). The sequences are analyzed
on 3500 or 3130 Dx Genetic Analyser® (Applied Biosystems).
The analytical chain was accredited according to Iso-Norm
15189 (agreement num: 8-1739) [18, 19].
Phospho-ERK analysis
Immunostaining was performed as described above, using
phospho-ERK1/2 antibody (Thr202/Tyr204) (1:800, D13.14.4E,
Cell signaling, Danvers, USA). For the western blot analysis,
total tumor lysates were generated as previously described [20].
Thirty micrograms of protein per sample were separated
electrophoretically in 4–15 % precast SDS polyacrylamide gels
and transferred to precut nitrocellulose membranes using the
Trans-Blot® turbo™ Transfer Starter System (all Bio-Rad).
Chemiluminescence and colorimetric detection were per-
formed using ChemiDoc™ MP Imaging System and horse-
radish peroxidase conjugated rabbit polyclonal anti-human p-
ERK1/2 (Thr202/Tyr204), ERK1/2 (1:1000) detected with
peroxidase-conjugated secondary anti-rabbit antibody, respect-
ively (1:1000; Cell Signaling Technology) and HRP conjugated
mouse monoclonal antibody anti-human β-Actin (S125; all
1:1000), followed by chemiluminescence solution (Clarity™
Western Chemiluminescent HRP Substrate; Bio-Rad).
Results
Clinical and neuroradiological features
Characteristics of the patients and controls are respect-
ively summarized in Tables 1 and 2.
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We analyzed four pediatric patients with PGNT, two
males and two females. Median age at diagnosis was 7 years
(range, 5–14). Symptoms at diagnosis were epilepsy (cases 1
and 3) and intracranial hypertension (cases 2 and 3). In the
case 4, the tumor has been revealed by an intracerebral
hematoma. Complete resection was reported in cases 1, 2
and 3. One patient received adjuvant radiotherapy and
presented a second location treated by surgery (case 1). The
follow-up times were respectively 6 years, 9 years, 3 years
and 9 months. At the time of the latest data, all patients
were alive. Initial MRIs of three cases of PGNT (cases 1, 2,
and 3) are shown in Fig. 1. No pre-operative imagery was
available for case 4. In cases 1, 2 and 3, the tumors appeared
as a well-demarcated tumor. All cases showed a ventricular
association, one is intraventricular (case 2) and in the two
others, the tumor had a contact with the temporal horn
ventricle (case 1 and 3) and presented a cyst component.
The three cases presented a contrast enhancing nodule.
Histology
Histological characteristics are summarized in Table 3.
All classical tumors classified as PGNT featured papillary
and solid areas, were biphasic and characterized by a GFAP
positive papillary glial component overlaying hyalinized
vessels. Interpapillary regions were exclusively composed
of homogeneous small cells, oligodendrocyte-like and
neurocyte-like cells, chromogranin and/or synaptophysin
positive and devoid of gangliocytoid and ganglioid cell fea-
tures (Fig. 2a). We observed exceptional eosinophilic
granular bodies in case 3 and hemorrhagic features in case
4. None of the four tumors showed malignant features. In
all cases, Olig2-expressing oligodendrocyte-like cells were
observed. An extravascular stellar expression of CD34 was
only present in case 3. Into the PGNT mimics group, we
took a particular attention in gangliogliomas with pseudo-
papillary features (cases 5 and 6). A ganglion cell compo-
nent was observed with chromogranin positive ganglioid
cells and binuclear cells. Abundant eosinophilic granular
bodies and an extravascular stellar expression of CD34
were observed in both cases (Fig. 2b). Case 6 also harbored
perivascular lymphoid infiltrates and hemorrhagic features.
SLC44A1-PRKCA FISH analysis
FISH analysis conducted on representative FFPE tissue sec-
tions of all PGNTs revealed a fusion of SLC44A1-PRKCA in
a high percentage of the tumor nuclei examined, indicating a
Table 1 Summary of PGNT cases: clinical and radiological characteristics and follow-up
Sex Age (y) Location Cyst GTR Clinical follow-up Status at follow-up
case 1 F 6 parietal yes yes radiotherapy, second location temporal treated by surgery NED (6 y)
case 2 M 8 intraventricular (V3) no yes - NED (9 y)
case 3 M 14 temporal yes yes residual micronodule non progressive (3 y)
case 4 F 5 parietal no no - NED (9 m)
F female, GTR gross total resection, M male, m month, NA not available, NED no evidence of disease, y year
Table 2 Summary of basic clinical characteristics of PGNT mimics cases
Sex Age (y) Location Diagnosis
case 5 M 4 chiasmatic ganglioglioma with papillary architecture
case 6 M 42 frontal ganglioglioma with papillary architecture
case 7 F 8 temporal + thalamopeduncular + chiasmatic ANET
case 8 F 16 tectal ANET
case 9 F 13 posterior fossa RGNT
case 10 F 14 hypothalamic and medullary metastases RGNT
case 11 F 19 intraventricular (V4) RGNT
case 12 F 14 cerebellar RGNT
case 13 M 13 intraventricular (V4) RGNT
case 14 M 14 pineal PRP
case 15 M 12 pineal PRP
case 16 F 6 3rd ventricle PE
case 17 F 15 parietal astroblastoma
case 18 F 17 intraventricular neurcytoma
case 19 M 15 intraventricular neurocytoma
ANET angiocentric neuroepithelial tumor, F female, M male, PE papillary ependymoma, PRP papillary tumor of the pineal region, RGNT rosette-forming glioneuronal
tumor of the fourth ventricle, y years
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rearrangement of these loci. Specifically, in cases 1, 2, 3 and
4, fusion signals were respectively observed in 82, 93, 74 and
77 %, of the counted nuclei, (Fig. 3a-d). Among these tu-
mors, two different profiles were identified; in cases 2 and 3
a majority of positive cells showed two fusion signals with
one pair of separated orange and green signals (Fig. 3b and
c). In cases 1 and 4, positive nuclei showed only one fused
orange/green signal accompanied by one separate orange
and two separate green signals (Fig. 3a and d).
In an effort to verify the specificity of the SLC44A1-
PRKCA fusion, FISH analysis was also performed on fifteen
PGNTs mimics cases (cases 5 to 19) and demonstrated that
none of these cases displayed the SLC44A1-PRKCA fusion
(Fig. 3e and f).
Immunohistochemical and molecular findings
Molecular findings are summarized in Table 4.
We analyzed the nuclear accumulation of p53 and
established the H3-K27 mutational status by immuno-
histochemistry; neoplastic cells were negative for both in all
PGNTs. Interestingly, the two gangliogliomas with pseudo-
papillary features, which are negative for SLC44A1-PRKCA
fusion, were BRAF mutation immunopositive (Fig. 4a). In
case 5, the c.1799 T >A (p.V600E) BRAF mutation was
confirmed by sequencing (but for case 6 DNA extraction
was of poor quality and sequencing failed). Conversely,
none of SLC44A1-PRKCA positive cases were positive for
the BRAF V600E mutation on immunostains, except case
4. In case 4, the BRAF mutation was not confirmed by
the sequencing analysis. Furthermore, we looked for
KIAA1549-BRAF fusion by RT-PCR on cases 1, 2, and 3.
None of those tumors showed the fusion. On immunos-
tainings, the cases 1, 2 and 3 showed a weak phospho-
FGFR1 expression (Fig. 4b) and the case 4 was negative. In
case 3, the labeling was present exclusively in the papillary
component while in the other it was diffusely present. None
of the PGNTs were positive for FGFR1 mutation by
sequencing. Exon 12 could not be analyzed in cases 1 et 2.
Phospho-ERK analysis
In all PGNTs, the tumor cells and particularly the papil-
lary components were strongly labeled with phospho-ERK
antibodies (Fig. 5a). These findings were confirmed by
western blotting (Fig. 5b) in all three cases analyzed (cases
1, 2, 3), indicating an activation of the MAPK-signaling
pathway.
Discussion
PGNT is a rare mixed glioneuronal tumor usually charac-
terized by an indolent clinical behavior [21]. The rarity and
the scarcity of tissue available for molecular and genetic
analyses have hampered the identification of specific
alterations. The diagnosis of PGNT is often difficult to
establish both on MRI and histology. On MRI, PGNT is
frequently described as a well-demarcated mass with a
cystic component, contrast enhancement, isointensity on
T1-weighted and a predominant location in the periven-
tricular area [22]. However, there is no pathognomonic
radiographic appearance and in the review by Carangelo
and colleagues, around 80 % of PGNT showed a
Fig. 1 Axial T1-weighted pre-operative MR images for cases 1, 2 and 3 with nodular contrast enhancement and showing a ventricular association
Table 3 Summary of histological and immunochemical characteristics
Ganglioid cells Granular bodies GFAP Synaptophysin Chromogranin CD34
case 1 - - + + + -
case 2 - - + + +/- -
case 3 - + + + - +
case 4 - - + + + +
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ventricular association [3]. All our cases show a ventricular
association, one is clearly intraventricular, similar to the
case reported by Matyja and colleagues [23] and the two
others, the tumor have a direct contact with the temporal
ventricle. The three cases present a nodular contrast
enhancement. Cases 1 and 3 show a more typical
appearance with a cystic component. According to the
WHO 2007 classification, PGNT is histologically charac-
terized by a distinct pseudopapillary architecture with
layers of GFAP positive glial elements, lining hyalinized
vessels and variable amount of interpseudopapillary
spaces filling by synaptophysin-positive neurocyte-like,
ganglioid, or ganglion cells [2]. However, microcystic
oligodendroglial-like areas and astrocytic components
could resemble to pilocytic astrocytoma or ANET. The
diagnosis is thus based on a set of histological and radio-
logical criteria. However, individual histological entities
could classically overlap with other LGG entities (PGNT
mimics). In particular, the distinction between PGNT and
ganglioglioma is not yet completely clear as in WHO
description, PGNT could contain a heterogeneously
distributed ganglion cell tumoral population [2]. Bridge
and colleagues identified a recurrent chromosomal trans-
location t(9;17)(q31;q24) in three PGNTs resulting in an
in-frame fusion of SLC44A1 and PRKCA, with consequent
generation of a constitutively expressed serine/threonine
Fig. 2 Histological and immunochemical characteristics. Serial sections from case 3 (a) showing a papillary architecture (H&E) with a GFAP
positive glial component overlaying hyalinized vessels, synaptophysin positive interpapillary regions, absence of chromogranin positive cells but a
CD34 extravascular expression. Serial sections from case 5 (b) showing a perivascular architecture and ganglion cells (H&E) with a GFAP positive
glial component overlaying hyalinized vessels, synaptophysin positive interpapillary regions, with numerous chromogranin positive ganglion
cells but an absence of CD34 extravascular expression. 2A, 2B GFAP, synaptophysin, CD34 magnification x100, 2B H&E, chromogranin
magnification x200
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kinase fusion [12]. A recent study has reported the pres-
ence of the fusion in two additional PGNTs [13]. Consist-
ent with this, our findings confirm the presence of
SLC44A1-PRKCA fusion in PGNT. We took a particular
attention in the group of PGNT mimics of two particular
cases of ganglioglioma with pseudopapillary features
(cases 5 and 6). Indeed, histological features of this entity
are similar to those of PGNT. However, interestingly, the
cases 5 and 6 did not show the SLC44A1-PRKCA fusion
but were BRAF V600E mutation positive, as described in
around 40 % of gangliogliomas [24]. Ganglioglioma is also
composed of neoplastic mature ganglion cells in com-
bination with neoplastic glial cells [25]. In our cases,
a ganglion cell component was observed only in cases
5 and 6 associated with eosinophilic granular bodies.
Conversely, positive cases for SLC44A1-PRKCA fusion
consisted exclusively of small oligodendrocyte-like
cells and neurocyte-like cells without gangliocytoid
and ganglioid cell features. Furthermore, case 6 showed an
extravascular expression of CD34, a marker consistently
expressed in 70–80 % of gangliogliomas, especially those
variants emerging from temporal lobe [26]. The neoplastic
cells from case 5, located in chiasmatic region, did not
express CD34. All these findings argue for definitively
classifying these two tumors as papillary variant form of
gangliogliomas, and to clearly separate them from PGNT.
Notably, it could be interesting as ganglioglioma represent
the single glio-neuronal tumoral entity susceptible to spon-
taneously present a malignant transformation [2]. Indeed,
relatively little is known about malignant changes in PGNT
[27]. Several cases with high proliferative activity have been
reported but all showed malignant features at diagnosis and
to our knowledge, no secondary malignant transformation
has been described in PGNT [28, 29]. Besides, molecular
data concerning malignant PGNT are very limited; BRAF
V600E mutation was screened in two cases which were
Fig. 3 Interphase FISH analysis in PGNT cases using SLC44A1 (green) and PRKCA (orange) dual-color probes (a and d) showing one SLC44A1-PRKCA
fusion signal (white arrows) accompanied by one separate orange and two separate green signals in cases 1 and 4. b and c showing two
SLC44A1-PRKCA fusion signals (white arrows) with one pair of separated orage and green signals in cases 2 and 3. e and f showing a lack of
SLC44A1-PRKCA fusion signal in cases 5 and 6. Magnification x600















case 1 + - - - + - -
case 2 + - - - + - -
case 3 + - - - + - -
case 4 + ND - - + - -
IHC immunohistochemistry, ND not done, WB western blot
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both negative [6]. Recurrent somatics alterations of FGFR1
are reported in pLGG [10] but no large pLGG cohort
studying FGFR1 mutational status have included some
PGNT. Contrary to the single case report describing a
FGFR1 N546K mutation (located in the exon 14) [11], we
did not find FGFR1 mutation in our cohort. No correlation
seems to exist between the presence of a mutation and a
positive immunostaining using phospho-FGFR1 antibody.
The identification of SLC44A1-PRKCA may also be
useful to distinguish PGNT from other tumors with
perivascular/angiocentric features.
In order to shed more light on the specificity of
SLC44A1-PRKCA fusion and its potential value in the dif-
ferential diagnosis of PGNT, we also investigated thirteen
additional cases of PGNT mimics. Particularly, we studied
five RGNTs cases that could be a differential diagnosis
due to the periventricular location and the biphasic pat-
tern. Two RGNTs cases have been previously tested for
SLC44A1-PRKCA fusion and were negative [13]. In our
cohort, none of ANETs, RGNTs, PRPs, PE, astroblastoma,
neurocytomas studied showed the SLC44A1-PRKCA fu-
sion, further supporting PGNT as a unique entity. PRKCA
Fig. 4 BRAF and phospho-FGFR1 immunostaining. a Immunohistochemistry on section from case 5 showing tumor cells stongly labeled in the
two components with an antibody against BRAF V600E. b Immunohistochemistry from case 1 showing the tumor immunoreactive with an antibody
against phospho-FGFR1. Magnification x200
Fig. 5 Phospho-ERK analysis. a Immunohistochemistry on section from case 1 showing a strong expression of phospho-ERK. Magnification x200. b
Total lysates from individual tumors (case 1, 2 and 3) were subjected to western blotting for expression analyses of phosphorylated (p-) and
non-phosphorylated ERK1/2. Pilocytic astrocytoma expressing KIAA1549-BRAF fusion was used as positive control (C+). ß-actin was used as reference
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is the alpha isoform of protein kinase C, a family member
of serine and threonine kinases that can be activated by
calcium and the second messenger diacylglycerol. PRKCA
can promote cell growth by phosphorylating and activat-
ing RAF1, which mediates the activation of the MAPK
signaling pathway. Therefore, deregulation or high consti-
tutive level of PRKCA expression secondary to fusion with
SLC44A1 could directly result in the deregulation of the
MAPK signaling pathway as observed in tumors showing
BRAF V600E mutation [30], notably gangliogliomas, or
KIAA1549-BRAF fusion as in pilocytic astrocytomas (PA)
[8]. In our cohort, phospho-ERK analysis provides argu-
ments for the activation of the MAPK signaling pathway.
MAPK pathway and BRAF status have been widely ex-
plored over the last few years showing that the histologic
spectrum of low grade gliomas and glioneuronal tumors
is vague but individualizing a group of low grade glioma
with MAPK signaling pathway deregulation. PGNT is a
rare entity which belongs to this group with MAPK
signaling pathway deregulation. SLC44A1-PRKCA fusion
alone could drive tumorigenesis, but additional studies
are needed to confirm this hypothesis.
Conclusions
In conclusion, in this study including clinico-radiological
and follow-up data, we have confirmed and extended the
molecular data on pediatric PGNT. We uphold the presence
of SLC44A1-PRKCA fusion in PGNT, which could represent
a novel model of single pathway disease as PA. SLC44A1-
PRKCA fusion seems to be specific for PGNT with a high
diagnostic value. As a consequence, we recommend investi-
gating it by FISH analysis for a diagnosis confirmation.
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